This clinical trial evaluates what type of outreach is best at increasing women getting a mammography. Breast cancer screens may help doctors find breast cancer sooner, when it may be easier to treat.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05089903.
PRIMARY OBJECTIVES:
I. To evaluate if centralized bulk ordering of mammograms increases response rate.
II. To evaluate if text messaging could increase uptake in addition to conventional outreach methods MyPennMedicine- MPM/letters).
III. To evaluate if an endorsement from the PCP increases response rate.
OUTLINE:
BULK ORDER TRIAL: Patients are randomized to 1 of 4 arms.
ARM 1 (No Order [NO]): Patients receive a letter or MyPennMedicine (MPM) signed by their primary care physician (PCP) informing them that they are due for a mammogram.
ARM 2 (No Order + Text [NO + T]): Patients receive a letter or MPM as in Arm 1, and receive a series of texts about the breast cancer screening until a mammogram is scheduled or completed.
ARM 3 (Bulk Order [BO]): Patients receive a mammogram booking and a letter of MPM as in Arm 1.
ARM 4 (Bulk Order + Text [BO + T]): Patients receive a mammogram booking, a letter or MPM as in Arm 1, and a series of texts about breast cancer screening until a mammogram is scheduled or completed.
CLINICAL ENDORSEMENT TRIAL (PRINCETON ONLY): Patients are randomized to 1 of 4 arms.
ARM 1 (Clinician Endorsement [CE]): Patients receive a letter or MPM signed by their PCP informing them that they are due for a mammogram.
ARM 2 (Clinician Endorsement + Text [CE + T]): Patients receive a letter or MPM as in Arm 1, and receive a series of texts about breast cancer screening until a mammogram is scheduled or completed.
ARM 3 (Standard Messaging [SM]): Patients receive a letter or MPM from the practice informing them that they are due for a mammogram.
ARM 4 (Standard Messaging + Text [SM+T]): Patients receive a letter or MPM from the practice, and receive a series of texts about breast cancer screening until a mammogram is scheduled or completed.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Pennsylvania/Abramson Cancer Center
Principal InvestigatorShivan J. Mehta